+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gene Therapy Market by Vector Type (Non-Viral Vectors, Viral Vectors), Treatment Modality (Germline Therapy, Somatic Cell Therapy), Target Genome, Delivery Mode, Route of Administration, Patient Type, Therapeutic Area, End-User - Global Forecast 2025-2030- Product Image
Gene Therapy Market by Vector Type (Non-Viral Vectors, Viral Vectors), Treatment Modality (Germline Therapy, Somatic Cell Therapy), Target Genome, Delivery Mode, Route of Administration, Patient Type, Therapeutic Area, End-User - Global Forecast 2025-2030- Product Image
Sale

Gene Therapy Market by Vector Type (Non-Viral Vectors, Viral Vectors), Treatment Modality (Germline Therapy, Somatic Cell Therapy), Target Genome, Delivery Mode, Route of Administration, Patient Type, Therapeutic Area, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4858031
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The gene therapy market is undergoing significant transformation, rapidly advancing due to scientific innovation, collaborative partnerships, and evolving regulatory guidance. As gene-based treatments move from experimental phases toward mainstream adoption, industry leaders face new challenges and opportunities that will shape the future landscape.

Market Snapshot: Gene Therapy Market Size and Growth Trajectory

The Gene Therapy Market grew from USD 10.31 billion in 2024 to USD 12.91 billion in 2025. It is expected to continue growing at a CAGR of 27.63%, reaching USD 44.61 billion by 2030. This sustained expansion is powered by increasing regulatory approvals, investment from both private and public sectors, and broader adoption of innovative therapies across multiple disease areas. Competitive differentiation lies in the ability to swiftly navigate policy shifts, advance technologies, and orchestrate enduring partnerships across the supply chain.

Scope & Segmentation of the Gene Therapy Market

This report delves into the market landscape across detailed segments and regions, offering in-depth analysis on technology, application, and stakeholder involvement.

  • Vector Type: Non-viral mechanisms (lipofection, plasmid DNA) and leading viral vectors (adeno-associated virus, adenovirus, herpes simplex virus, retrovirus).
  • Treatment Modality: Coverage of germline and somatic cell therapies, including gene augmentation and suppression approaches.
  • Target Genome: Focus on both DNA and RNA-based editing or modulation therapies.
  • Delivery Mode: Assessment of ex vivo and in vivo strategies for target tissue reach and efficacy.
  • Route of Administration: Evaluation of intramuscular, intraocular, and intravenous methodologies to optimize delivery and effectiveness.
  • Patient Type: Insights into adult and pediatric patient cohorts, reflecting immunogenicity and trial design considerations.
  • Therapeutic Area: Exploration across cardiovascular, infectious, monogenic, and oncological disease portfolios.
  • End-User: Examination of hospitals, clinics, contract research organizations, biopharma companies, and research institutes as critical players in development and adoption.
  • Regional Coverage: Americas (U.S., Canada, Mexico, Brazil, Argentina), Europe Middle East & Africa (including UK, Germany, France, UAE, South Africa), Asia-Pacific (China, India, Japan, Australia, South Korea, others).
  • Company Profiles: Review of market impact and pipeline progress across industry leaders such as Abeona Therapeutics, Amgen, Biogen, CRISPR Therapeutics, Novartis, and emerging startups.

Key Takeaways for Senior Leaders

  • Strategic partnerships between public institutions, large pharmaceutical companies, and contract development organizations increasingly drive pipeline development and clinical success in gene therapy.
  • Emerging genomic technologies, such as CRISPR/Cas and advanced viral vector engineering, are setting new standards in safety, targeting, and manufacturing scalability.
  • Production costs and supply chain complexity remain challenges, yet industry-wide adoption of modular bioprocessing and automation is improving speed and resilience.
  • Regulatory innovation, including expedited pathways and special designations, is enabling faster approval timelines but demands proactive compliance and adaptive trial design.
  • Patient stratification by disease area, therapy modality, and cohort (adult or pediatric) is increasingly important for maximizing clinical outcomes and market reach.
  • Market opportunity extends beyond monogenic disorders into cardiovascular, infectious, and oncological areas, requiring robust segmentation strategies.

Tariff Impact: Supply Chain and Cost Realignment

In 2025, tariffs on critical bioprocessing components such as viral vectors and reagents introduced new cost pressures for U.S.-based and global gene therapy developers. Companies are responding by reconsidering supply sources, forming cost-sharing alliances, stockpiling inputs, or investing in domestic production to reduce long-term exposure to trade disruptions. While short-term complexity has increased, these policies are reinforcing a shift toward localized, vertically integrated manufacturing networks.

Methodology & Data Sources

This report synthesizes primary interviews with industry executives, academic leaders, and regulators, alongside in-depth secondary research from peer-reviewed sources, clinical trial data, and financial documents. Triangulation and validation methods deliver a balanced and reliable analysis combining quantitative and qualitative insights.

Why This Report Matters for Decision Makers

  • Offers a holistic understanding of emerging gene therapy technologies, patient segments, and partnership models to inform business development and investment strategy.
  • Guides market entry and expansion decisions by mapping regulatory trends, regional dynamics, and end-user adoption factors.
  • Supports risk management through up-to-date analysis of policy shifts and their effects on procurement, timelines, and operational planning.

Conclusion

Gene therapy is poised to become a defining segment within precision medicine, reshaping care standards across multiple indications. Equipped with robust analysis, stakeholders can align strategies to capture growth and advance patient-focused innovation in an evolving landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advancements in CRISPR base editing enabling precise single-base corrections in inherited disorders
5.2. Emergence of lipid nanoparticle delivery systems improving gene therapy targeting efficiency and safety
5.3. Clinical success of AAV vector therapies reducing immune response through novel capsid engineering
5.4. Integration of AI-driven bioinformatics in gene therapy design to optimize vector specificity and potency
5.5. Regulatory approval pathways evolving for in vivo gene editing therapies across major global markets
5.6. Expansion of ex vivo CAR T gene-modified cell therapies into solid tumors with novel target antigen strategies
5.7. Adoption of non-viral delivery methods such as electroporation and nanoparticle conjugates to reduce manufacturing costs
5.8. Growth of personalized gene therapies driven by advanced genomic profiling and patient-specific vector customization
5.9. Strategic partnerships between biotech and big pharma accelerating late-stage gene therapy clinical pipelines
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Gene Therapy Market, by Vector Type
8.1. Introduction
8.2. Non-Viral Vectors
8.2.1. Lipofection
8.2.2. Plasmid DNA
8.3. Viral Vectors
8.3.1. Adeno-Associated Virus (AAV) Vectors
8.3.2. Adenovirus Vectors
8.3.3. Herpes Simplex Virus (HSV) Vectors
8.3.4. Retrovirus Vectors
9. Gene Therapy Market, by Treatment Modality
9.1. Introduction
9.2. Germline Therapy
9.3. Somatic Cell Therapy
9.3.1. Gene Augmentation Therapy
9.3.2. Gene Suppression Therapy
10. Gene Therapy Market, by Target Genome
10.1. Introduction
10.2. DNA Modification
10.3. RNA Modification
11. Gene Therapy Market, by Delivery Mode
11.1. Introduction
11.2. Ex Vivo
11.3. In Vivo
12. Gene Therapy Market, by Route of Administration
12.1. Introduction
12.2. Intramuscular
12.3. Intraocular
12.4. Intravenous
13. Gene Therapy Market, by Patient Type
13.1. Introduction
13.2. Adult Patients
13.3. Pediatric Patients
14. Gene Therapy Market, by Therapeutic Area
14.1. Introduction
14.2. Cardiovascular Diseases
14.2.1. Coronary Artery Disease
14.2.2. Heart Failure
14.3. Infectious Diseases
14.3.1. Hepatitis B
14.3.2. HIV
14.4. Monogenic Disorders
14.4.1. Cystic Fibrosis
14.4.2. Hemophilia
14.4.3. Sickle Cell Anemia
14.5. Oncological Disorders
14.5.1. Hematological Malignancies
14.5.2. Solid Tumors
15. Gene Therapy Market, by End-User
15.1. Introduction
15.2. Contract Research Organizations
15.3. Hospitals & Clinics
15.4. Pharmaceutical & Biotech Companies
15.5. Research Institutes
16. Americas Gene Therapy Market
16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. Argentina
17. Europe, Middle East & Africa Gene Therapy Market
17.1. Introduction
17.2. United Kingdom
17.3. Germany
17.4. France
17.5. Russia
17.6. Italy
17.7. Spain
17.8. United Arab Emirates
17.9. Saudi Arabia
17.10. South Africa
17.11. Denmark
17.12. Netherlands
17.13. Qatar
17.14. Finland
17.15. Sweden
17.16. Nigeria
17.17. Egypt
17.18. Turkey
17.19. Israel
17.20. Norway
17.21. Poland
17.22. Switzerland
18. Asia-Pacific Gene Therapy Market
18.1. Introduction
18.2. China
18.3. India
18.4. Japan
18.5. Australia
18.6. South Korea
18.7. Indonesia
18.8. Thailand
18.9. Philippines
18.10. Malaysia
18.11. Singapore
18.12. Vietnam
18.13. Taiwan
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. Abeona Therapeutics Inc.
19.3.2. Adaptimmune Therapeutics PLC
19.3.3. Adverum Biotechnologies, Inc.
19.3.4. AGC Biologics
19.3.5. Alnylam Pharmaceuticals, Inc.
19.3.6. American Gene Technologies Inc.
19.3.7. Amgen Inc.
19.3.8. AnGes, Inc.
19.3.9. Astellas Pharma Inc.
19.3.10. Biogen Inc.
19.3.11. bluebird bio, Inc.
19.3.12. Cellectis S.A.
19.3.13. CRISPR Therapeutics AG
19.3.14. Danaher Corporation
19.3.15. Editas Medicine, Inc.
19.3.16. F. Hoffmann-La Roche Ltd.
19.3.17. Gilead Sciences, Inc.
19.3.18. Intellia Therapeutics
19.3.19. Ionis Pharmaceuticals, Inc.
19.3.20. Johnson & Johnson
19.3.21. Merck KGaA
19.3.22. Mustang Bio, Inc.
19.3.23. Novartis AG
19.3.24. Orchard Therapeutics PLC
19.3.25. Poseida Therapeutics, Inc.
19.3.26. Sangamo Therapeutics, Inc.
19.3.27. Sarepta Therapeutics, Inc.
19.3.28. Sibiono GeneTech Co. Ltd.
19.3.29. Syncona Limited
19.3.30. ViGeneron GmbH
19.3.31. Voyager Therapeutics Inc.
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. GENE THERAPY MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 18. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 20. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 31. GENE THERAPY MARKET: RESEARCHAI
FIGURE 32. GENE THERAPY MARKET: RESEARCHSTATISTICS
FIGURE 33. GENE THERAPY MARKET: RESEARCHCONTACTS
FIGURE 34. GENE THERAPY MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. GENE THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GENE THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL GENE THERAPY MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL GENE THERAPY MARKET SIZE, BY LIPOFECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL GENE THERAPY MARKET SIZE, BY LIPOFECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL GENE THERAPY MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL GENE THERAPY MARKET SIZE, BY PLASMID DNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL GENE THERAPY MARKET SIZE, BY ADENOVIRUS VECTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL GENE THERAPY MARKET SIZE, BY ADENOVIRUS VECTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL GENE THERAPY MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL GENE THERAPY MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL GENE THERAPY MARKET SIZE, BY RETROVIRUS VECTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL GENE THERAPY MARKET SIZE, BY RETROVIRUS VECTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL GENE THERAPY MARKET SIZE, BY GERMLINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL GENE THERAPY MARKET SIZE, BY GERMLINE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL GENE THERAPY MARKET SIZE, BY GENE AUGMENTATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL GENE THERAPY MARKET SIZE, BY GENE AUGMENTATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL GENE THERAPY MARKET SIZE, BY GENE SUPPRESSION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL GENE THERAPY MARKET SIZE, BY GENE SUPPRESSION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL GENE THERAPY MARKET SIZE, BY DNA MODIFICATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL GENE THERAPY MARKET SIZE, BY DNA MODIFICATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL GENE THERAPY MARKET SIZE, BY RNA MODIFICATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL GENE THERAPY MARKET SIZE, BY RNA MODIFICATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL GENE THERAPY MARKET SIZE, BY EX VIVO, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL GENE THERAPY MARKET SIZE, BY EX VIVO, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL GENE THERAPY MARKET SIZE, BY IN VIVO, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL GENE THERAPY MARKET SIZE, BY IN VIVO, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAOCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAOCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL GENE THERAPY MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL GENE THERAPY MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL GENE THERAPY MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL GENE THERAPY MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL GENE THERAPY MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL GENE THERAPY MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL GENE THERAPY MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL GENE THERAPY MARKET SIZE, BY HEART FAILURE, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL GENE THERAPY MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL GENE THERAPY MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL GENE THERAPY MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL GENE THERAPY MARKET SIZE, BY HIV, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL GENE THERAPY MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL GENE THERAPY MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL GENE THERAPY MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL GENE THERAPY MARKET SIZE, BY HEMOPHILIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL GENE THERAPY MARKET SIZE, BY SICKLE CELL ANEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL GENE THERAPY MARKET SIZE, BY SICKLE CELL ANEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL GENE THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL GENE THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL GENE THERAPY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL GENE THERAPY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL GENE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL GENE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS GENE THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS GENE THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS GENE THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES GENE THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES GENE THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 179. CANADA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 180. CANADA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 181. CANADA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 182. CANADA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 183. CANADA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 184. CANADA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 185. CANADA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 186. CANADA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 187. CANADA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 188. CANADA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 189. CANADA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2024 (USD MILLION)
TABLE 190. CANADA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2025-2030 (USD MILLION)
TABLE 191. CANADA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
TABLE 192. CANADA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2025-2030 (USD MILLION)
TABLE 193. CANADA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 194. CANADA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 195. CANADA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 196. CANADA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 197. CANADA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 198. CANADA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 199. CANADA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
TABLE 200. CANADA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2030 (USD MILLION)
TABLE 201. CANADA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 202. CANADA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 203. CANADA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 204. CANADA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 205. CANADA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 206. CANADA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 207. CANADA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 208. CANADA GENE THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 209. MEXICO GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 210. MEXICO GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 211. MEXICO GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 212. MEXICO GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 213. MEXICO GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 214. MEXICO GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 215. MEXICO GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 216. MEXICO GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 217. MEXICO GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 218. MEXICO GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 219. MEXICO GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2024 (USD MILLION)
TABLE 220. MEXICO GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2025-2030 (USD MILLION)
TABLE 221. MEXICO GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
TABLE 222. MEXICO GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2025-2030 (USD MILLION)
TABLE 223. MEXICO GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 224. MEXICO GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 225. MEXICO GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 226. MEXICO GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 227. MEXICO GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 228. MEXICO GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 229. MEXICO GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
TABLE 230. MEXICO GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2030 (USD MILLION)
TABLE 231. MEXICO GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 232. MEXICO GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 233. MEXICO GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 234. MEXICO GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 235. MEXICO GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 236. MEXICO GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 237. MEXICO GENE THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 238. MEXICO GENE THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 239. BRAZIL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 240. BRAZIL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 241. BRAZIL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 242. BRAZIL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 243. BRAZIL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 244. BRAZIL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 245. BRAZIL GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 246. BRAZIL GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 247. BRAZIL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 248. BRAZIL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 249. BRAZIL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2024 (USD MILLION)
TABLE 250. BRAZIL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2025-2030 (USD MILLION)
TABLE 251. BRAZIL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
TABLE 252. BRAZIL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2025-2030 (USD MILLION)
TABLE 253. BRAZIL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 254. BRAZIL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 255. BRAZIL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 256. BRAZIL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 257. BRAZIL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 258. BRAZIL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 259. BRAZIL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
TABLE 260. BRAZIL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2030 (USD MILLION)
TABLE 261. BRAZIL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 262. BRAZIL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 263. BRAZIL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 264. BRAZIL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 265. BRAZIL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 266. BRAZIL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 267. BRAZIL GENE THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 268. BRAZIL GENE THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 269. ARGENTINA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 270. ARGENTINA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 271. ARGENTINA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 272. ARGENTINA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 273. ARGENTINA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 274. ARGENTINA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 275. ARGENTINA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 276. ARGENTINA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 277. ARGENTINA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 278. ARGENTINA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 279. ARGENTINA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2024 (USD MILLION)
TABLE 280. ARGENTINA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2025-2030 (USD MILLION)
TABLE 281. ARGENTINA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
TABLE 282. ARGENTINA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2025-2030 (USD MILLION)
TABLE 283. ARGENTINA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 284. ARGENTINA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 285. ARGENTINA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 286. ARGENTINA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 287. ARGENTINA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 288. ARGENTINA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 289. ARGENTINA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
TABLE 290. ARGENTINA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2030 (USD MILLION)
TABLE 291. ARGENTINA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 292. ARGENTINA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 293. ARGENTINA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 294. ARGENTINA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 295. ARGENTINA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 296. ARGENTINA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 297. ARGENTINA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 298. ARGENTINA GENE THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 299. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 300. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 301. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 302. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 303. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 304. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 305. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 306. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 307. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 308. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 309. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2024 (USD MILLION)
TABLE 310. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2025-2030 (USD MILLION)
TABLE 311. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
TABLE 312. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2025-2030 (USD MILLION)
TABLE 313. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 314. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 315. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 316. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 317. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 318. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 319. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
TABLE 320. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2030 (USD MILLION)
TABLE 321. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 322. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 323. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 324. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 325. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 326. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 327. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 328. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 329. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 330. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 331. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 332. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 333. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 334. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 335. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 336. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 337. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 338. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 339. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 340. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 341. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2024 (USD MILLION)
TABLE 342. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2025-2030 (USD MILLION)
TABLE 343. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
TABLE 344. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2025-2030 (USD MILLION)
TABLE 345. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 346. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 347. UN

Samples

Loading
LOADING...

Companies Mentioned

  • Abeona Therapeutics Inc.
  • Adaptimmune Therapeutics PLC
  • Adverum Biotechnologies, Inc.
  • AGC Biologics
  • Alnylam Pharmaceuticals, Inc.
  • American Gene Technologies Inc.
  • Amgen Inc.
  • AnGes, Inc.
  • Astellas Pharma Inc.
  • Biogen Inc.
  • bluebird bio, Inc.
  • Cellectis S.A.
  • CRISPR Therapeutics AG
  • Danaher Corporation
  • Editas Medicine, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Intellia Therapeutics
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Merck KGaA
  • Mustang Bio, Inc.
  • Novartis AG
  • Orchard Therapeutics PLC
  • Poseida Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Sibiono GeneTech Co. Ltd.
  • Syncona Limited
  • ViGeneron GmbH
  • Voyager Therapeutics Inc.

Table Information

Report AttributeDetails
No. of Pages184
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 12.91 Billion
Forecasted Market Value ( USD ) by 2030 $ 44.61 Billion
Compound Annual Growth Rate27.6%
Regions CoveredGlobal
No. of Companies Mentioned31

Related Topics

Related Reports

Cell & Gene Therapy Manufacturing Services Market by Service Type (Analytical & Quality Control Services, Cell Banking Services, Consulting Services), Technology Type (Gene Editing, Vectors), Therapeutic Area, Application, End-User - Global Forecast 2025-2030 - Product Image

Cell & Gene Therapy Manufacturing Services Market by Service Type (Analytical & Quality Control Services, Cell Banking Services, Consulting Services), Technology Type (Gene Editing, Vectors), Therapeutic Area, Application, End-User - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
Gene Delivery Technologies Market by Delivery Vector Type (Non-Viral Vector, Viral Vector), Therapeutic Application (Cardiovascular Therapies, Genetic Disorders, Oncology), Product, End User, Technology - Global Forecast 2025-2030 - Product Image

Gene Delivery Technologies Market by Delivery Vector Type (Non-Viral Vector, Viral Vector), Therapeutic Application (Cardiovascular Therapies, Genetic Disorders, Oncology), Product, End User, Technology - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Gene Therapy Market Size, Share, Trends and Forecast by Gene Type, Vector Type, Delivery Method, Application, and Region, 2025-2033 - Product Image

Gene Therapy Market Size, Share, Trends and Forecast by Gene Type, Vector Type, Delivery Method, Application, and Region, 2025-2033

  • Report
  • 140 Pages
  • Global
From
Gene Therapy - Global Strategic Business Report - Product Image

Gene Therapy - Global Strategic Business Report

  • Report
  • 411 Pages
  • Global
From
Gene Therapy Market Report 2025 - Product Image

Gene Therapy Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.